Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...

Most newly diagnosed patients with focal epilepsy continued to have seizures for a year or more after starting antiseizure medications (ASMs), results from the latest Human Epilepsy Project (HEP) ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neuromodulation offers personalized, responsive ...

Briviact (brivaracetam) is a brand-name drug prescribed to treat partial (focal onset) seizures in adults and children. Briviact comes in several dosage forms and is typically taken twice per day.

Keppra (levetiracetam) is a brand-name drug that’s prescribed for certain types of seizures in adults and some children. Keppra comes as an oral tablet and oral solution that’s typically taken twice ...

When older adults living in nursing homes are prescribed the pain medicine tramadol alongside certain antidepressants, their risk of seizures may go up, according to a study published October 8, 2025, ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...